SINGULAR GENOMICS SYSTEMS, INC. Financials Singular Genomics Systems, Inc.
Equities
OMIC
US82933R1005
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4118 USD | -8.06% |
|
-0.31% | -10.50% |
| 03-20 | UBS Adjusts Singular Genomics Systems Price Target to $0.50 From $0.40, Maintains Neutral Rating | MT |
| 03-18 | Transcript : Singular Genomics Systems, Inc., Q4 2023 Earnings Call, Mar 18, 2024 |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 833 | 143.5 | 33.76 | 30.51 | - | - |
| Enterprise Value (EV) 1 | 503.7 | 79.31 | 33.76 | 29.72 | 55.64 | 63.42 |
| P/E ratio | -5.5 x | -1.57 x | -0.35 x | -0.35 x | -0.39 x | -0.55 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | 188 x | 11.6 x | 12.6 x | 2.15 x | 0.86 x |
| EV / Revenue | - | 104 x | 11.6 x | 12.3 x | 3.92 x | 1.78 x |
| EV / EBITDA | -8.37 x | -0.87 x | -0.34 x | -0.3 x | -0.66 x | -0.7 x |
| EV / FCF | -8,904,402 x | -851,682 x | - | - | - | - |
| FCF Yield | -0% | -0% | - | - | - | - |
| Price to Book | 2.49 x | 0.55 x | - | - | - | - |
| Nbr of stocks (in thousands) | 72,059 | 71,396 | 73,385 | 74,085 | - | - |
| Reference price 2 | 11.56 | 2.010 | 0.4601 | 0.4118 | 0.4118 | 0.4118 |
| Announcement Date | 02/03/22 | 02/03/23 | 18/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 0.765 | 2.911 | 2.419 | 14.18 | 35.66 |
| EBITDA 1 | - | -60.15 | -91.06 | -99.29 | -98.6 | -84.8 | -90 |
| EBIT 1 | - | -61.28 | -93.49 | -102.8 | -91.03 | -85.31 | -82.48 |
| Operating Margin | - | - | -12,220.52% | -3,531.47% | -3,763.15% | -601.53% | -231.3% |
| Earnings before Tax (EBT) 1 | - | - | -90.88 | -94.82 | -85 | -88 | -93 |
| Net income 1 | -27.94 | -98.77 | -90.88 | -94.82 | -87.71 | -82.22 | -79.44 |
| Net margin | - | - | -11,879.61% | -3,257.3% | -3,625.75% | -579.7% | -222.79% |
| EPS 2 | -2.640 | -2.100 | -1.280 | -1.300 | -1.165 | -1.065 | -0.7450 |
| Free Cash Flow | - | -56.56 | -93.12 | - | - | - | - |
| FCF margin | - | - | -12,172.03% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 22/03/21 | 02/03/22 | 02/03/23 | 18/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | 0.765 | 0.863 | 0.505 | 0.462 | 1.081 | 0.694 | 0.4375 | 0.6815 | 0.9565 |
| EBITDA 1 | -17.16 | -19.31 | -21.56 | -23.63 | -24.06 | -21.81 | -24.58 | -26.73 | -23.67 | -24.3 | -23.9 | -25.7 | - | - |
| EBIT 1 | -17.46 | -19.67 | -22.02 | -24.24 | -24.69 | -22.53 | -25.38 | -27.6 | -24.54 | -25.28 | -25.89 | -22.14 | -20.83 | -21.18 |
| Operating Margin | - | - | - | - | - | -2,945.1% | -2,940.67% | -5,465.94% | -5,311.47% | -2,338.67% | -3,730.4% | -5,061.03% | -3,056.71% | -2,214.69% |
| Earnings before Tax (EBT) | -17.61 | - | - | -23.98 | - | -21.1 | -23.63 | -25.58 | -22.36 | -23.25 | - | - | -19 | -19 |
| Net income | -17.61 | - | -22.01 | -23.98 | -23.79 | -21.1 | -23.63 | -25.58 | -22.36 | -23.25 | - | - | -19 | -19 |
| Net margin | - | - | - | - | - | -2,758.3% | -2,738.47% | -5,064.95% | -4,839.83% | -2,150.69% | - | - | -2,787.97% | -1,986.41% |
| EPS 2 | -0.2500 | -0.2700 | -0.3100 | -0.3400 | -0.3300 | -0.2900 | -0.3300 | -0.3500 | -0.3100 | -0.3100 | -0.3500 | -0.3000 | -0.2700 | -0.2650 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 09/11/21 | 02/03/22 | 10/05/22 | 09/08/22 | 07/11/22 | 02/03/23 | 09/05/23 | 09/08/23 | 14/11/23 | 18/03/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 25.1 | 32.9 |
| Net Cash position 1 | - | 329 | 64.2 | - | 0.79 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | -0.2963 x | -0.3657 x |
| Free Cash Flow | - | -56.6 | -93.1 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | -69.4% | -30.5% | - | - | - | - |
| ROA (Net income/ Total Assets) | - | -51.2% | -26.6% | - | - | - | - |
| Assets 1 | - | 193.1 | 341.8 | - | - | - | - |
| Book Value Per Share | - | 4.640 | 3.620 | - | - | - | - |
| Cash Flow per Share | - | -1.100 | -1.220 | - | - | - | - |
| Capex | - | 4.86 | 6.02 | - | - | - | - |
| Capex / Sales | - | - | 787.19% | - | - | - | - |
| Announcement Date | 22/03/21 | 02/03/22 | 02/03/23 | 18/03/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.4118
USD
Average target price
0.85
USD
Spread / Average Target
+106.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.50% | 30.51M | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- OMIC Stock
- Financials Singular Genomics Systems, Inc.
